Łotwa - łotewski - Pārtikas un veterinārais dienests, Zemkopības ministrija

sabiedrības “arkopharma” grupa “nutripharma ltd” - kapsula

Łotwa - łotewski - Pārtikas un veterinārais dienests, Zemkopības ministrija

sd pro, sia - pulveris

Łotwa - łotewski - Zāļu valsts aģentūra

ebewe pharma ges.m.b.h nfg.kg, austria - metotreksāts - Šķīdums injekcijām pilnšļircē - 20 mg/ml

Łotwa - łotewski - Pārtikas un veterinārais dienests, Zemkopības ministrija

sd pro, sia 40003866209 madonas ielā 10a - 4, rīga, lv - 1035, latvija - pulveris - cits - paredzēts lietošanai intensīvas muskuļu piepūles gadījumos, īpaši sportistiem, kā papildus olbaltumvielu, minerālvielu un vitamīnu avots.

Unia Europejska - łotewski - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - un imūnglobulīni, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. skatīt nodaļas 4. 4 un 5.

Unia Europejska - łotewski - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - obesity; overweight - pretiekaisuma līdzekļi, izņemot diētas produkti - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to.

Łotwa - łotewski - Zāļu valsts aģentūra

wörwag pharma gmbh & co.kg, germany - sitagliptīns - apvalkotā tablete - 25 mg

Łotwa - łotewski - Zāļu valsts aģentūra

wörwag pharma gmbh & co.kg, germany - sitagliptīns - apvalkotā tablete - 50 mg

Łotwa - łotewski - Zāļu valsts aģentūra

wörwag pharma gmbh & co.kg, germany - sitagliptīns - apvalkotā tablete - 100 mg

Unia Europejska - łotewski - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatīts, atopisks - citi dermatoloģiski preparāti - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.